Sleep Disorders

The study is the first to support the validity of the ESS-CHAD in pediatric participants under the age of 12 years, showing internal consistency, test-retest reliability, responsiveness to change, and construct validity.

Neurology News Network for the week ending January 29, 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 28, 2022.

The light intervention was found to reduce awakening time at night, delay sleep offset, and advance sleep onset in a small patient population with dementia.

Chronic medical comorbidities, more commonly found in patients with obstructive sleep apnea, have been associated with higher readmission and healthcare utilization rates.

After adjusting for baseline scores, no significant correlation emerged between the changes on Epworth Sleepiness Scale and the number of hours of CPAP use.

Investigators developed a weighted logistic regression-based sleep-wake scoring method for actigraphy data, concluding that it aided in assessing sleep in CP.

Panelists review suboptimal over-the-counter medications that patients may use to manage insomnia.

A brief discussion on the use of mind and body practices to aid in the management of insomnia.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

Expert perspectives on the benefits of and limitations to cognitive behavioral therapy for insomnia.

Focusing on treatment options for insomnia, experts consider the added value of sleep hygiene.

Here's what is coming soon to NeurologyLive®.

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 14, 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Roth, PhD. [LISTEN TIME: 12 minutes]

Daridorexant, which will be marketed as Quviviq, will be available later this year after being scheduled by the US Drug Enforcement Administration.

Panelists discuss the broad range of impact insomnia has on a patient’s health and quality of life.

A brief review of the value of polysomnography, or sleep studies, in diagnosing patients with insomnia.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 7, 2022.

The Jazz Pharmaceuticals’ product, which was FDA approved in August 2021, demonstrated clinically meaningful differences compared with placebo on several secondary end points, including impression of change scales and various and questionnaires.

The authors noted that future studies should investigate this association to identify patients with obstructive sleep apnea who are at risk of potential cognitive decline and adverse health function.